AAN and AHS update migraine prevention guideline
Analysis based on 7 articles · First reported Aug 31, 2026 · Last updated Sep 08, 2026
The guideline may increase prescription rates for migraine preventive medications, potentially benefiting pharmaceutical companies that manufacture these drugs. It also reinforces the clinical importance of newer treatment classes, possibly influencing market share and investment in migraine therapeutics.
On August 31, 2026, the American Academy of Neurology (AAN) and the Headache (journal) (AHS) jointly published an updated clinical practice guideline on pharmacologic treatment for migraine prevention in adults. The guideline, which updates the 2012 version, appears in Neurology and Headache journals and is endorsed by the American Academy of Family Physicians. It provides evidence-based recommendations for both chronic and episodic migraine, incorporating newer preventive medications alongside established ones. The update emphasizes offering preventive treatment to adults with four or more migraine days per month or significant functional impairment, and encourages shared decision-making considering efficacy, side effects, cost, and comorbidities. The guideline was authored by experts including Tamara Pringsheim, Rebecca C. Burch, and others, and was funded by the AAN.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard